Effects of Shenmai Injection Combined with Interleukin-2 on the Immune Function and Life Quality of Lung Cancer Patients Underwent Postoperative Chemotherapy
YAO Yang, WANG Xiao-hua, ZHOU Qiang
Department of Oncology, Suining Central Hospital, Suining ,Sichuan , China, 629000
Abstract：【Objective】To explore the effects of Shenmai injection combined with interleukin-2 on immune function, chemotherapy toxicity and quality of life in patients with lung cancer undergoing postoperative chemotherapy. 【Methods】Eighty-two patients with non small cell lung cancer treated in our hospital were divided into the observation group and the control group . Based on the operation, the control group was treated with postoperative chemotherapy and intrapleural injection of IL-2 , while the observation group recieved IL-2 intrapleural injection combimed with Shenmai injection. The clinical efficacy were compared between the two groups. 【Results】The total response rate in the treatment of pleural effusion in the observation group was 83.3%, higher than that in the control group (62.5%) (P<0.05). There were no significant differences in immune function and quality of life scores between the two groups before treatment (P>0.05); After treatment, there were no significant changes in the control group (P>0.05).The function scale CD3+、CD4+、CD4+/CD8+, the overall quality of life scale score of the observation group after treatment were higher; Symptom scale, single scale score and CD8+ were lower than those before treatment and those of the control group after treatment (P<0.05). The incidence of nausea and vomiting Ⅲ in the observation group was 4.8% (2/42) and 7.1% (3/42), which was lower than that in the control group 20.0% (8/40) and 30% (12/40), and the difference was significant (P<0.05). There was no significant difference in the incidence of other adverse reactions between the two groups (P > 0.05).【Conclusion】The application of Shenmai injection combined with interleukin-2 in the treatment of lung cancer can effectively alleviate pleural effusion, enhance patient's immune ,improve patient's tolerance and reduce the toxic and side effects.
姚阳;王晓华;周强;杜雄. 参麦注射液联合白介素-2对肺癌术后化疗患者免疫功能及生活质量的影响[J]. 医学临床研究, 2016, 33(12): 2357-2361,2363.
YAO Yang, WANG Xiao-hua, ZHOU Qiang. Effects of Shenmai Injection Combined with Interleukin-2 on the Immune Function and Life Quality of Lung Cancer Patients Underwent Postoperative Chemotherapy. JOURNAL OF CLINICAL RESEARCH, 2016, 33(12): 2357-2361,2363.
[1] 张慧君,陈晓峰,刘鸿程,等.164例小细胞肺癌术后预后分析[J].临床肺科杂志,2010,15(8):1073-1074. [2] 中国抗癌协会.新编常见恶性肿瘤诊治规范(合订本)[M].中国协和医科大学出版社,1999:92-95. [3] Vassalou H,Stathopoulos E,Fiolitaki G,et al.Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy[J].Lung Cancer,2013,82(2):324-329. [4] 邢军,陆辉辉,李文韬,等.肺癌恶性胸腔积液胸腔镜下胸腔内循环灌注化疗临床分析[J].医学临床研究,2012,29(5):902-904,908. [5] 马楠.化疗联合DC-CIK治疗老年晚期非小细胞肺癌的疗效评价[J].解放军医药杂志,2015,27(1):37-40. [6] 陈传喜,袁红,杨志勇,等.吉西他滨与奥沙利铂联合三维适形同步放化疗治疗Ⅲ期非小细胞肺癌的临床观察[J].西部医学,2014,26(4):442-444. [7] Mori K,Kamiyama Y,Kasai H,et al.A phase II study of first-line chemotherapy with weekly carboplatin plus gemcitabine in advanced non-small cell lung cancer[J].Chemotherapy,2012,58(1):78-83. [8] 肖创清,蒋立,黄志红,等.肺癌患者化疗前后血清ES和CYFRA21-1改变的临床意义[J].湖南师范大学学报(医学版),2013,10(3):51-52,55. [9] 梁秋萍,殷俊.EGFR TKI+TP方案及TP方案对晚期非小细胞肺癌治疗临床效果及肿瘤标志物水平的影响[J].成都医学院学报,2016,11(1):40-44. [10] 张婉露,严天虹,刘斌,等.参麦注射液联合化疗方案治疗非小细胞肺癌疗效的系统评价和Meta分析[J].实用药物与临床,2011,14(2):95-101.
2016, Vol. 33 
